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ABSTRACT
This	paper	is	aimed	at	examining	the	European	medicine	agency	decisions	in	the	field	of	human	medicines.	
Different	classes	of	human	medicines	approved	in	the	last	five	years	have	been	classified.	They	have	been	
analyzed	considering:	i)	the	relation	between	non	generic	drugs	and	generic	drugs,	ii)	time	of	approval,	iii)	
objectives	of	the	clinical	trials,	iv)	criteria	of	efficiency,	efficacy,	safety.	By	using	the	Summary	of	the	European	
Public	Assessment	Report	for	every	human	medicine	in	the	period	2010-2015,	a	dataset	has	been	arranged.	
A	Structural	Equation	Model	analysis	was	carried	out.	The	degree	of	efficiency,	the	degree	of	safety,	the	
tradeoff	between	efficiency	and	safety	that	lead	to	the	EMA	approval	decisions	are	conditioned	by	the	nature	
of	the	medicines	and	the	characteristics	of	their	class.	Different	degrees	of	benefits	and	risks	underpinning	the	
decisions	have	been	identified	together	with	the	consequent	guiding	principles	that	lead	to	the	EMA	decision	
process.	A	latent	general	“safety”	factor	at	the	basis	of	EMA	decision	process	was	assessed.
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INTRODUCTION
Regulatory agencies play a crucial role in the approval of human medicines and, at the same 
time, in health care. The process leading to a regulatory outcome is guided by the benefit/risk 
assessment, which is a complex process based on the assessment of non-clinical, clinical and 
quality data submitted by the pharmaceutical manufacturer. In the case of authorized-for-use 
drugs, benefits must outweigh risks. A proper assessment of the risk/benefit ratio combines ob-
jective evidence and subjective elements, leading to decisions that should be reproducible and 
transparent. These are communicated to the various stakeholders (Trotta et al, 2011).
A huge literature has dealt with decision making processes adopted by regulatory authori-
ties. The topics range from the criteria underpinning the decisions (Beyer, 2011; EMA, 2011; 
Leong et al, 2013; Tafuri et al 2014; Menon, 2015), to the design and the evaluation of different 
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frameworks for decision making process (EMA 2007; C.I.R.S., 2011; Leong et al, 2015). Little 
has been said about the outcome. To date, no theoretical account of when and in what circum-
stances decisions may be taken has been offered in the literature.
This paper is aimed at examining the European Medicine Agency (EMA) decisions in the 
field of human medicines. The objective is twofold: on one hand three characteristics of human 
medicine approved in the last five years have been classified: i) the relation between non generic 
and generic drugs, ii) the time of approval, iii) objectives of the clinical trials – namely – mea-
sures of efficacy. Different degrees of benefits and risks underpinning the decisions have been 
identified through different guiding principles. The development of these principles guides the 
decision process. The last step has been to understand if and how these principles are implemented 
uniformly considering the characteristics of the drugs. A dataset was assembled using the human 
medicine reports on the EMA website. This work presents the first results.
MATERIALS AND METHODS
The EMA Framework
By checking EMA website, the public assessments about human medicines have been analyzed. 
We limited our investigation to human medicines that were submitted for approval in the past 
five years, accepting the EMA criteria of classification1. Terms like i) efficacy, ii) efficiency, iii) 
effectiveness, for example, were used with their general meanings, respectively i) reproducing 
an effect consistently, ii) measuring the performance of the process of conversion of inputs into 
outputs, iii) measuring the degree to which the outputs satisfy requirements.
Three hundred and fifteen medicines were classified in different therapeutic groups accord-
ing to the organ or system on which they act. The classification was arranged on the anatomical 
groupings which ATC Code2 takes into account. In this way we have considered 14 groups: 1) 
Alimentary tract and metabolism, 2) Blood and forming organs, 3) Cardiovascular system, 4) 
Dermatological, 5) Genitourinary system and sex hormones, 6) Systemic hormonal preparations 
excluding sex hormones and insulins, 7) Anti-infective for systemic use, 8) Antineoplastic, 9) 
Musculoskeletal system, 10) Nervous system, 11) Anti-parasitic, 12) Respiratory system, 13) 
Sensory organs, and 14) Others not classified.
The Balance of Risks and Benefits that Leads to a 
Decision. A Brief Review of the Literature
The assessment of the benefits and the risks associated with a medicine is defined as benefit-risk 
assessment (BRA). Benefit-risk balance, or benefit risk ratio evaluation are different ways to 
define the same kind of evaluation. BRA is an evaluation of two dimensions. The dimension of 
benefits is measured primarily in terms of therapeutic efficacy, i.e. the successful treatment of 
the condition for which the drug is indicated (Curtin, Schultz, 2011). There are other types of 
benefits, such as improvement of quality of life or pharmaco-economic aspects. The dimension 
of risks includes the safety profile: adverse event, severe adverse event, and discontinuation 
rate due to adverse event. The potential risk of unobserved events should also be considered. 
What we define as “balance” in theory does not indicate a real equilibrium in practice, nor does 
it have comparable measures. Cheung and Kumana (2001), for example, argued that a minimal 
benefit can never be attractive, even if there is a 99% chance of occurrence. On the other hand, 
a tiny risk, say 1%, cannot always be ignored, especially if the penalty is something unpleasant. 
Similarly, Herxheimer (2001) stated that benefits and risks have completely different dimen-
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sions: a benefit is a material or experiential good thing, while a risk is a probability, the chance 
that something bad will happen. Therefore ‘benefit’ should be weighed against ‘harm’, along 
with the probability of benefit against the probability of harm. Edwards et al. (1996) went one 
step further and argued that the phrase ‘benefit–risk’ is clumsy and has been used in too many 
different contexts. By examining several attempts to quantify BRA, they argue that no method 
provides a fully satisfactory solution regarding BRA, because it is difficult to reduce its multi-
dimensional aspect to simple metrics, in a context where other therapeutic alternatives play a 
role. The preferred term was therefore ‘merit assessment’ since it unambiguously indicates the 
determination of the worth of a medicine in a given context.
As a matter of fact, perceptions of risks versus benefits are influenced to a great extent by 
the context in which they occur, and may be different to actual risk. In any given situation, the 
acceptable risk-to-benefit balance is an individual judgement on the part of the patient or the 
prescriber.
Benefit–harm balance is a more general and therefore more appropriate term, which is used 
for example in the new EU pharmaceutical legislation. Benefit-harm is defined as ‘an evaluation 
of the positive therapeutic effects of the medicinal product in relation to the risks’, with risks 
being defined as ‘any risk relating to the quality, safety and efficacy of the medicinal product as 
regards the health of patients’ (Council of the European Union, 2003). In the European Union, 
medicines must meet the three exclusive criteria laid down in the Community Law which are: 
quality, safety and efficacy, for a marketing authorization to be granted (Brunet, 1999). In Di-
rective 2001/83/EC of the Community Code relating to medicinal products for human use, it is 
stipulated that a marketing authorization shall be refused if: (a) the risk–benefit balance is not 
considered to be favorable, or (b) its therapeutic efficacy is insufficiently substantiated by the 
applicant, or (c) its qualitative and quantitative composition is not as declared by the common 
core elements upon which all the frameworks are based .
Therefore, it is clear that the regulatory decisions are the outcome of a balancing the benefits: 
e.g., the effectiveness of the drug and the risk; and the safety that the medicines bring. At the 
same time, it is clear that effectiveness and safety are variable values depending on the kinds of 
medicines and the kinds of care which medicines are aimed at.
Approval decisions for public safety are made considering different levels of efficacy or 
different levels of safety, until the low levels of ineffectiveness and unsafety lead to denial of 
authorization.
Within the range where benefits are greater than risks there are many possible combina-
tions. High levels of efficiency may be combined with high, medium and low levels of safety, 
and vice-versa.
Structural Equation Model (SEM) Analysis
SEM analysis (Pugesek, Tomer, von Eye, 2003) supplies information as a causal modeling of the 
processes under study, represented by a series of structural (i.e., regression) equations, which can 
also be pictorially modeled to enable a more clear conceptualization of the theory. Unlike most 
other multivariate procedures that are essentially descriptive by nature, this process is confirma-
tory (i.e., hypothesis-testing), rather than exploratory in terms of data analysis. The hypothesized 
model can then be tested statistically in a simultaneous analysis of the entire system of variables 
to determine the extent to which it is consistent with the data.
Whereas traditional multivariate procedures are incapable of either assessing or correcting 
for measurement error, SEM provides explicit estimates of these error variance parameters. 
Methods such as those rooted in regression, or the general linear model, assume that errors in 
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the explanatory (i.e., independent) variables vanish; so errors in the explanatory variables are 
ignored, leading to serious inaccuracies.
A good fitting model is one that can reproduce the original variance-covariance matrix (or 
correlation matrix) from the path coefficients, in much the same way that a good factor analytic 
solution can reproduce the original correlation matrix with little error. Parameters were estimated 
by maximum likelihood, an iterative procedure which attempts to maximize the likelihood that 
obtained values of the criterion variable will be correctly predicted.
The IBM_SPSS_22 and AMOS software packages were used for the statistical analyses.
RESULTS
The Amount of Generic and non-Generic Medicines
We examined the percentage of drugs approved for every therapeutic area, distinguishing between 
generic and non-generic medicines according to ATC Code. As shown in Table 1, the percentage 
of antineoplastic medicines (ATC Code 8) is the highest (23.1%). The treatment of cancer and 
other degenerative diseases, such as multiple sclerosis, is included in this group. Both medicines 
for the alimentary tract and metabolism (ATC Code 1) and anti-infective for systemic use (ATC 
Code 7) have the same percentage in the field of non-generic medicines (11.4%), but different 
percentages in the field of generic medicines (respectively 3.5% vs 1.2%). Among others, the 
treatment of obesity and diabetes mellitus are included in the first group, as the treatment of HIV 
and HCV are included in the second one.
The percentage of non-generic medicines compared with generic ones is mainly modest or 
even zero. A reverse distribution concerns medicines grouped in Musculoskeletal system (ATC 
Code 9), and in Nervous system (ATC Code 10), where the percentages of generic drugs are, 
Table	1.	Percentage	distribution	OF	APPROVALS	between	generic	and	non-generic	medicines	
by	ATC	Code
ATC Code NOT GENERIC GENERIC
1. Alimentary tract and metabolism 11.4 3.5
2. Blood and forming organs 4.3 0.0
3. Cardiovascular system 6.3 1.6
4. Dermatological 2.0 0.0
5. Genitourinary system and sex hormones 2.0 0.4
6. Systemic hormonal preparations excluding sex hormones and insulins 1.2 0.0
7. Anti-infective for systemic use 11.4 1.2
8. Antineoplastic 20.0 3.1
9. Musculoskeletal system 1.6 4.3
10. Nervous system 7.9 6.8
11. Respiratory system 5.5 0.0
12. Sensory organs 2.7 0.0
13. Others not classified 2.7 0.0
TOTAL 78.8 20.8
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respectively, higher (4.3 vs 1.6) and just lower (6.7 vs 7.8) than the percentages of non-generic 
drugs. In both cases the percentages are the highest in absolute terms, among generic drugs. To 
name but a few, treatments for bone metastasis (ATC Code 9), Parkinsons and Alzheimer diseases 
(ATC Code 10) are included in these groups. This should be of particular concern.
Today long-established treatments for diseases like Parkinson and Alzheimer are out of date 
and, as EMA reports, in both cases non-generic drugs aim at reducing the numbers of symptoms 
and at slowing down the progress of the disease, so that, when medicines able to recovery lack, 
the result is an abundant supply of generic drugs. Moreover, when the patents of the routine 
drugs are probably expired, the outcome is certainly a greater number of corresponding generics. 
On the contrary, with more recently discovered diseases, grouped in anti-infective drugs (ATC 
Code 7) such as Hepatitis C or HIV, drug patents may still be exclusive. In this case the approval 
of a greater number of generic forms would be premature. With time the recovery target should 
reduce the drug request and the market intake of generic medicines.
But, in the class of antineoplastic drugs, for example, where, though treatments aim at the 
care of old diseases, the target of medicines is, in many cases, to extend life of the patients or 
just to improve the quality of their life, statistics are different. In fact, even if circumstances 
are favorable to a market intake of generic drugs, in this case the number of generic drugs in 
comparison with not generic ones is only one-sixth.
Another explanation is also possible. In the case of musculoskeletal group (ATC Code 9) 
the high number of generic drugs is not counterbalanced by non-generic ones: probably little 
has been invested in research for new drugs.
Something of analogous occurs for what concerns drugs grouped in the nervous system 
category (ATC Code 10). Although generic drugs are 7% on the total of non-generic medicines, 
representing the third category in absolute terms, the corresponding generic medicines are just 
as many, representing the most significant category in the corresponding group. Such as high 
proportion of generic drugs may indicate that new treatments of certain diseases are currently 
missing. New medicines probably show the same efficiency degree of the older ones which are 
replicated in the generic medicines.
Despite the interesting considerations about generic medicines, our analysis was limited to 
the consideration of the amount of generic drugs with respect to the non-generic ones. The other 
characteristics we take account of, refer to non-generic drugs, inasmuch they show different 
level of risk/benefit ratios in their approval process. As a matter of fact the approval procedure 
of generic drugs consists in a bioequivalence comparison with the non-generic ones and with the 
risk/benefit ratio evaluated for the last ones. Table 2 shows the diseases contained in the most 
representative ATC Code classes for generic and non-generic medicines.
Time of Approval
Table 3 shows the EMA’s approval trends of the non-generic medicines. Columns from 1 to 5 
refer to the lapse of time from submission to approval: 1 means 6 months from submission, 2 
means a time from 6 months to 1 year, 3 means a time from 1 year to 1 and a half year, 4 means 
a time from 1.5 year to 2 years, 5 means a time beyond 2 years. It should be noted that for EMA 
2 years is the deadline time and so approval time beyond this period is considered a guilty delay.
The majority of drugs (42.08%) is approved in a medium time (column 3), during a time 
from 1 year to one and an half year. Comparing column 2 and column 4 it results that EMA 
authorizes more drugs in minor time (22.8 vs. 19.3) and that there are more authorizations 
within 6 months (column 1) from submission than beyond the deadline (column 5, 8.9 vs. 6.9). 
Excluding ATC Code 10 (2.5% in column 1), both authorization dates in column 1 and in column 
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Table	2.	Diseases	included	in	the	most	representative	ATC	Code	classes	with	percentages	of	
Generic	/	non	Generic	drugs
ATC Code Disease Generic Not Generic Total
     2. Alimentary tract and metabolism Total 2.55 14.85 17.40
Diabetes Mellitus type 2 1.86 7.42 9.28
Obesity 0.46 4.18 4.64
Others 0.23 3.25 3.48
3. Cardiovascular system           Total 0.46 7.42 7.89
Heart Failure 0.00 0.46 0.46
Pulmonary Hypertension 0.00 0.93 0.93
Dysplidemias 0.00 0.46 0.46
Hypercholesterolemia 0.00 1.39 1.39
Hypertension 0.46 4.18 4.64
7. Anti-infective for systemic use Total 0.70 18.09 18.79
Cystic Fibrosis 0.00 1.39 1.39
C Epatithis 0.00 4.64 4.64
Hiv infection 0.23 4.64 4.87
Influenza 0.23 1.39 1.62
Meningite 0.00 1.86 1.86
Tubercolosis 0.00 1.39 1.39
Others 0.23 2.78 3.02
8. Antineoplastic Total 2.09 37.12 39.21
Lymphoma non Hodgkin 0.00 2.32 2.32
Breast Neoplasm 0.00 1.86 1.86
Carcinoma Small Cell 0.46 4.18 4.64
Colorectal Cancer 0.00 0.93 0.93
Glaucome 0.00 1.86 1.86
Graft Rejection 0.00 1.86 1.86
Leucemia 1.16 3.25 4.41
Melanoma 0.00 2.32 2.32
Multiple Sclerosis 0.00 1.86 1.86
Myeloma 0.00 2.32 2.32
Neutrophenia 0.00 2.78 2.78
   Ovarian Cancer 0.00 1.86 1.86
   Pancreatic Cancer 0.00 0.93 0.93
   Prostatic Cancer 0.00 3.25 3.25
   Pulmonary Fibrosys 0.00 0.46 0.46
   Rheumoatoid Arthris 0.23 0.93 1.16
   Soft Tissue Sarcoma 0.00 0.93 0.93
continued	on	following	page
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5 are homogeneously distributed. ATC Code 12 is almost integrally concentrated in the second 
semester (column 2, 4%), whereas ATC Code 7 has the same percentage (4.95%) in column 2 
and column 3, more than in column 4 (3.5%). A similar trend can be observed for ATC Code 
8: the value is 7.9 in column 1, greater than the value in column 4 (4.5%) and little minor than 
that in column 3 (10.9%).
Measure of Efficacy
By means of efficacy we intended to quantify the primary objectives pursued by the trials of 
the pharmaceutics industries to obtain the approval of EMA. Items were ranked taking account 
of the trial reports and in the majority of cases they coincide with the primary endpoints. They 
consist of five groups (Table 4), building up a hierarchically scale: 1 stands for cure rate, 2 for 
the disease progression rate, 3 for overall survival, 4 represents the percentage of reduction of 
the number of the symptoms, 5 stands for the quality of life. Considering subtotals, the major 
percentage of drugs was found in the group 2 (disease progression rate), and ATC Code 1 (Ali-
mentary tract and metabolism) has the greatest value: 9.47%. It is not surprising to find the major 
percentage, 9.47, of antineoplastic drugs (ATC Code 8) in the group 3 standing for the overall 
survival. Anti-infective drugs for systemic use (ATC Code 7) have the greatest percentage, 6.51, 
in the group 1, measuring the care rate. On the contrary, drugs belonging to the ATC Code 10 
(nervous system) have both the subtotal and the total greatest percentage in the group 4. The cure 
of symptoms is a less ambitious objective than the reduction of the disease or at least making it 
stationary. There are not many drugs pursuing the improvement of quality of life (QoL). Drugs 
that do improve QoL are mainly concentrated in the ATC Code 1 (column 6, 1.78%).
Identifying Efficiency: Recognizing the Value of the Benefits
Approval decision involves, above all, an efficiency evaluation of the medicine. Consulting the 
summaries of the European Public Assessment Report (EPAR) for every human medicine in the 
period 2010-2015, we went back to evaluation methods by which European Agency assessed 
the medicine to recommend its authorization in the EU and its conditions of use. Answering to 
ATC Code Disease Generic Not Generic Total
   Stomach Cancer 0.00 1.39 1.39
   Uterine Neoplasm 0.23 0.00 0.23
   Others 0.00 1.86 1.86
10. Nervous system Total 4.18 12.53 16.71
   Alzheimer 1.39 1.39 2.78
   Epilepsy 1.86 1.86 3.71
   Multiple Sclerosis 0.70 1.39 2.09
   Parkinson 0.23 2.78 3.02
   Schizophrenia 0.00 2.32 2.32
   Others 0.00 2.78 2.78
Total 9.98 90.02 100
Table	2.	Continued
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the question “why medicine has been approved”, EMA says: 1) the medicine is effective, 2) the 
medicine has a modest/limited in time/effectiveness, 3) the medicine has a relevant efficiency/
more than another medicine/ or evaluated without a comparison, 4) in case of generic drug: the 
medicine is in line with a similar product, 5) in case of non-generic drug: the medicine has a 
comparable efficiency with others, 6) the medicine can be used as alternative to other medicines, 
7) the medicine represents a second line treatment to other medicines, 8) improvement efficiency 
has been demonstrated when used in combination with other medicines, 9) the medicine is not 
sufficient in efficiency.
We assembled the answers in four levels of efficiency: 1) high level of efficiency/high 
level of benefits that includes answers 3, 6, 8; 2) medium level that includes answers 1,4,5; 3) 
low level that includes answers 2, 7, and finally 4) less than low level of efficiency/ benefit that 
includes answer 9.
Identifying Safety: The Kind of Risks
Moreover, approval decision involves an identification and an evaluation of the drug safety. Also 
in this case it has been utilized the Summary of the European Public Assessment Report (EPAR) 
for every human medicines in the period 2010-2015, and the corresponding list of items useful 
to understand the value given to every risk that can prejudice the safety of the medicine. From 
Table	3.	Items	by	authorization	date	distributed	according	to	the	ATC	Code
Atc 
Code
Authorization Date (Percentages) Total
6 Months 6 Months 
To 1 Year
1 Year to 
1.5 Year
1.5 Year 
t o  2 
Years
Beyond 2 
Years
1. Alimentary tract and 
metabolism
1.0 2.0 8.9 1.5 1.0 14.4
2. Blood and forming organs 0.0 0.0 4.0 1.5 0.0 5.4
3. Cardiovascular system 1.0 1.0 2.5 2.0 1.5 7.9
4. Dermatological 0.0 0.0 1.5 0.0 1.0 2.5
5. Genitourinary system and 
sex hormones
0.5 0.0 0.5 1.0 0.5 2.5
6. Systemic hormonal 
preparations excluding sex 
hormones and insulins
0.0 0.0 0.0 1.5 0.0 1.5
7. Anti-infective for systemic 
use
1.0 5.0 5.0 3.5 0.5 14.9
8. Antineoplastic 1.0 7.9 10.9 4.5 1.0 25.2
9. Musculoskeletal system 0.0 0.5 1.0 0.5 0.0 3.0
10. Nervous system 2.5 1.5 3.5 2.0 0.5 9.9
12. Respiratory system 1.0 4.0 1.5 0.0 0.5 6.9
13. Sensory organs 0.0 0.5 2.0 0.5 0.5 3.5
14. Others not classified 1.0 0.5 1.0 1.0 0.0 3.5
Total 8,9 22.8 42.1 19.3 6.9 100.0
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the answers to the questions “why medicine has been approved” and “what are the risks of the 
medicines”, we caught the following degrees of safety, mainly linked to the side effect risks3. 
They are standardized, as for the efficiency assessment: 1) side effects are totally manageable, 
2) side effects are largely manageable, 3) there is some concern for some side effect, 4) side 
effect are well tolerated, 5) side effects are acceptable, 6) side effects are local, 7) (specifically 
for generic) side effects are comparable with the original medicine, 8) lack of comparable medi-
cine side effects, 9) as combination of two or more medicines, side effects are well known, 10) 
easily/ resolving in short time, 11) side effects or some side effect is toxic, 12) side effects are 
unmanageable.
We also assembled the answers in four levels of safety: 1) high level which includes answers 
1, 7, 8, 10; 2) medium, including answers 2, 4, 6, 9; 3) low, including answers 3, 5; 4) less than 
Table	4.	Items	for	the	measure	of	efficacy	distributed	(percentages)	according	to	the	ATC	Code
ATC Code Efficacy Total
Cure rate
Disease 
Progression 
Rate
Overall 
Survival
Reduction of 
the Number 
of the 
Symptoms
Quality 
of Life
1. Alimentary tract 
and metabolism
4.14 9.47 0.59 0.00 1.78 15.98
2. Blood and forming 
organs
0.59 2.96 0.59 1.18 0.00 5.33
3. Cardiovascular 
system
1.78 1.78 0.59 1.78 0.00 5.92
4. Dermatological 1.78 0.59 0.00 0.59 0.00 2.96
5. Genitourinary 
system and sex 
hormones
0.59 0.00 0.00 0.59 0.59 1.78
6. Systemic 
hormonal 
preparations 
excluding sex 
hormones and 
insulins
0.59 1.18 0.00 0.00 0.00 1.78
7. Anti-infective for 
systemic use
6.51 5.92 1.18 1.18 0.00 14.79
8. Antineoplastic 4.73 8.88 9.47 2.96 0.00 26.04
9. Musculoskeletal 
system
0.59 1.78 0.00 0.00 0.00 2.37
10. Nervous system 1.18 1.78 0.59 4.73 0.59 8.88
12. Respiratory 
system
1.18 5.33 0.00 0.59 0.00 7.10
13. Sensory organs 1.18 1.18 0.00 0.59 0.00 2.96
14. Others not 
classified
0.00 2.96 0.59 0.59 0.00 4.14
Total 24.85 43.79 13.61 14.79 2.96 100
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low, including answers 11, 12. Safety furthermore may be divided in Safety 1 and Safety 2, 
because EMA definitions of security about risks are duplex, so each level of safety splits in two.
Table 5 shows the relation between Efficiency and Safety 1, expressed as percentages accord-
ing to the ATC Code, meanwhile Table 6 shows the analogous relation with Safety 2. Efficiency 
levels 1, 2, 3 agree with the approval of the drug, whereas level 4 stands for the refusal of the drug 
because of its substantial inefficiency. In Table 5 at the highest levels of Efficiency and Safety 
1 corresponds a percentage of 13.04, lesser than that of low level of Safety 1 (14.13%). On the 
contrary, as shown in Table 6, the highest level of Efficiency corresponds to the highest level of 
Safety 2, 17.58%, even though the low level of Safety 2 shows a value of 13.58%. Generally, at 
the other levels of Efficiency the percentages of low Safety noticeably decrease.
In both Tables it is shown that approval decisions with high Efficiency evaluations are in 
the same percentages of approval decisions with medium Efficiency, even though the last one 
is related to highest levels of Safety that then decrease to medium level, low level, and in less 
than low level, in the approval decisions with low Efficiency. From Table 5 and Table 6 it can 
be maintained that the higher is the Efficiency level, more side effects are admitted, and then the 
lesser Safety. The First Guiding Principle of EMA decision can be deduced:
1.  Raising the benefits, major risks can be tolerated.
And as a corollary:
2.  Decreasing the benefits, risks must decrease too.
Moreover, for what concerns ATC Code 8 (antineoplastic drugs), its behavior is like aggre-
gate data: a lesser Safety for a higher Efficiency. Table 5, at high Efficiency level shows 5.43% 
for low level of Safety, vs 0.54 of high level of Safety. In Table 6 high Safety and low Safety 
are respectively 7.41% and 6.17%. Moreover, from both Table 5 and 6 Safety increases in high 
and medium levels for decreasing levels of Efficiency. On the contrary, the distribution of ATC 
Code 7 (anti-infective drugs) is different: for high Efficiency level, Safety 1 is decreasing in the 
high, medium and low levels, whereas Safety 2 increases in the same levels, showing an opposite 
behavior. Interestingly, ATC Code 10 (nervous system) and ATC Code 3 (cardiovascular sys-
tem), are mainly concentrated in the medium level of Efficiency, with medium and low levels of 
Safety. A possible explanation may derive from data in Table 2. As a matter of fact, anti-infective 
drugs are not versus fatal diseases as instead are antineoplastic drugs. So, probably the Safety 
level for approval is necessarily higher on average. We, therefore, can update the above guiding 
principles including these ones:
1.  High levels of benefits are related to high levels of risk especially in case of fatal diseases;
2.  With high benefits and not fatal diseases, the risks should not be very high.
As a corollary we can add a third principle:
3.  For drugs of medium level of efficacy, reference diseases should not be fatal.
Other inquiries are probably necessary to explain the trends of the medium-low levels of 
Safety and Efficacy Level 3 (Overall survival), and of nervous system drugs.
Copyright © 2015, IGI Global. Copying or distributing in print or electronic forms without written permission of IGI Global is prohibited.
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Further Indication about Safety/Efficiency
EMA supplies further indications about the efficiency and the safety of the drugs. Its content is 
negative or at least dubitative, that is to say that EMA approving a drug singles out grounds for 
caution. It is a case of conditional approval, with very low percentages, as shown in Table 7. It 
has been utilized the Summary of the European Public Assessment Report (EPAR) for every hu-
man medicines in the period 2010-2015, and the corresponding list of items useful to understand 
the value given to every risk that can prejudice the safety of the medicine. Here are the answers 
to the question “why the drug was approved”: 1) not sure it works with a particular subgroup, 
2) not proved its efficiency when combined or compared, 3) not proved efficiency in secondary 
use, 4) only to use in specialized centers of control, 5) not proved the efficiency on the progress 
of the disease or in long time, 6) data is partial, 7) some particular side effect should be further 
investigated or limited the use. 1-2-3-5- were grouped in a hierarchical way under the heading 1 
“partial efficiency”, 6 under the heading 2 “partial data”, 4-7 under the heading 3 “partial safety”. 
This means that Efficiency and Safety values, up to now considered, cannot have an absolute 
value. As shown in Table 7, just the 3.5% of drugs were conditional approved, whereas Table 8 
shows the percentages of Further Indication Levels according to the ATC Code.
Table 9 is very interesting. It shows that the major percentage of Further Indication is related 
to high levels of Efficiency, decreasing at low levels of Efficiency.
Then we need once more to update the Guiding Principles. The first one will sound like 
this: High levels of Efficiency, whether partially or scarcely proved, can come with low levels 
of Safety, in a few cases also partially or scarcely proved. And the second one: Safety increases 
with medium levels of Efficiency, meanwhile decreasing the conditions under which Efficiency 
and Safety are partially and scarcely proved.
Table	7.	Conditional	approval	percentages	of	drugs
Conditional Approval
ATC Code YES NO Total
1. Alimentary tract and metabolism 0.00 14.43 14.43
2. Blood and forming organs 0.00 5.47 5.47
3. Cardiovascular system 0.00 7.96 7.96
4. Dermatological 0.00 2.49 2.49
5. Genitourinary system and sex hormones 0.00 2.49 2.49
6. Systemic hormonal preparations excluding 
sex hormones and insulins
0.00 1.49 1.49
7. Anti-infective for systemic use 0.50 13.93 14.43
8. Antineoplastic 1.99 23.38 25.37
9. Musculoskeletal system 0.00 1.99 1.99
10. Nervous system 0.50 9.45 9.95
12. Respiratory system 0.00 6.97 6.97
13. Sensory organs 0.50 2.99 3.48
14. Others not classified 0.00 3.48 3.48
Total 3.48 96.52 100
Copyright © 2015, IGI Global. Copying or distributing in print or electronic forms without written permission of IGI Global is prohibited.
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Low levels of Efficiency now come with low levels of Further Indication (differently from 
the Safety trend): low Efficiency cannot get worse because of “partial data” or “partial safety”, 
otherwise the drug should be not approved.
ATC Code 7, 8 and 10 have the higher percentages of further indication that come with 
high levels of efficiency.
SEM Analysis
SEM analysis was carried out by taking into account seven observed variables: Efficiency, 
Efficacy, Safety 1, Safety 2, Further Indication, Authorization Date, Revision, as endogenous 
variables, and two unobserved exogenous variables F1 and F2.
We hypothesized that there were two unobserved latent factors (one for timing, F1, and 
one for safety, F2) that underlay the observed variables as described in Figure 1. Authorization 
Date and Revision load on F1 (with loadings (a.k.a. Regression Weights), see Table 10, 0.34 
and -0.19 respectively). Safety 1, Safety 2, Further indication, load on F2 (with loadings 0.69, 
0.29, and 0.55 respectively). The double headed arrow indicates the covariance between the 
two latent factors (F1 and F2). e1 through e7 represent the residual variances (variance in the 
observed variables not accounted for by the two latent factors). We set the variances of F1 and 
F2 equal to 1 so that the parameters will have a scale. This will result in F1 and F2 representing 
the correlation between the two latent factors (.91).
Table	8.	Percentages	of	further	indication	levels	according	to	the	ATC	Code
ATC Code
No Further 
Indication
Further Indication
Partial 
Efficiency
Partial 
Data
Partial 
Safety
Total
1. Alimentary tract and 
metabolism
9.50 2.00 1.00 1.50 14.00
2. Blood and forming organs 4.00 0.50 0.00 1.00 5.50
3. Cardiovascular system 6.50 0.50 1.00 0.00 8.00
4. Dermatological 1.50 0.00 0.50 0.50 2.50
5. Genitourinary system and 
sex hormones
1.50 0.50 0.00 0.50 2.50
6. Systemic hormonal 
preparations excluding sex 
hormones and insulins
0.50 1.00 0.00 0.00 1.50
7.  Ant i - infect ive  for 
systemic use
8.50 3.50 0.50 2.00 14.50
8. Antineoplastic 15.50 5.50 1.50 3.00 25.50
9. Musculoskeletal system 1.00 0.50 0.50 0.00 2.00
10. Nervous system 8.00 1.50 0.50 0.00 10.00
12. Respiratory system 3.00 2.50 1.00 0.50 7.00
13. Sensory organs 2.50 0.00 1.00 0.00 3.50
14. Others not classified 1.50 1.50 0.00 0.50 3.50
Total 63.50 19.50 7.50 9.50 100
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The path coefficients of the SEM model show that Efficiency is significantly affected by 
Safety1 (path coefficient = 0.20) and Safety2 (path coefficient = 0.31). Moreover, the three safety 
criteria: Safety 1, Safety 2, Further indication, are significantly affected by the latent factor F2 
(path coefficients = 0.69, 0.29, 0.55, respectively).
DISCUSSION
With the help of Table 11 we can now integrate the guiding principles that are likely to have 
oriented EMA decisions:
1.  Higher efficiency agrees with lower safety. This is true i) even if efficiency is partial, as 
described above, ii) particularly when the medicines belong to an ATC Code class (i.e. 8, 
antineoplastic drugs) including fatal diseases. Low life expectancy is typical of those ATC 
Codes whose main measure of efficacy is level 3: “overall survival”.
2.  If efficiency is equally high and eventually partial but the medicines belong to ATC Codes 
with a major life expectancy, safety is typically medium-high. This is particularly true for 
those medicines whose main measure of efficacy is level 1: “care rate”.
Figure	1.	Path	Diagram.	Significant	Standardized	Regression	Weights	are	asterisked.
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3.  When efficiency is medium, safety has to be high and increasing with the lack of further 
indications. As said above, as a matter of fact, medium efficiency is incomplete in itself to 
be effected by further limits. When efficiency is medium, it is typically related to classes of 
ATC Code with low risk of life threatening conditions and with a high life expectancy: i.e. 
hypertension, obesity, in ATC Code 1 and 3.
The condition of medium-low efficiency related to a low level of safety is particularly true 
for ATC Code classes 1 and 10, where treatments are intended to be used for psychiatric and 
neurological disorders (i.e. epilepsy, schizophrenia), elderly diseases (Alzheimer, Parkinson) 
and diseases with a major mortality among older peoples (diabetes, obesity).
From the results of the SEM model (see Figure 1 and Table 10) we can surmise that at the 
basis of EMA’s decisions there is a latent “safety” factor (inasmuch it significantly affects Safety 
1, Safety 2 and Further Indication) as a determinant of the efficiency criterion.
CONCLUSION
A general model of the determinants of efficiency and efficacy criteria that lead to the EMA 
approval decisions was assessed. Different degrees of benefits and risks underpinning the EMA 
decisions have been identified together with the consequent guiding principles that lead to the 
decision process. Our findings give evidence of a latent general “safety” factor in the background 
of EMA’s decision process.
Table	10.	Standardized	regression	weights	estimations,	presented	with	their	p-values	as	appear-
ing	in	Path	Diagram
Determinants Standardized 
Regression Weights
p
Authorisation date <--- F1 .342 .090
Revision <--- F1 -.189 .133
Safety1 <--- F2 .692 .002
Safety2 <--- F2 .295 .048
Further indication <--- F2 .550 .002
Efficiency <--- Authorization date .005 .944
Efficiency <--- Safety1 .199 .020
Efficiency <--- Revision -.005 .945
Efficacy <--- Further indication -.120 .334
Efficacy <--- Safety2 -.029 .787
Efficacy <--- Revision -.057 .428
Efficacy <--- Authorization date -.005 .947
Efficiency <--- Further indication -.066 .585
Efficiency <--- Safety2 .305 .002
Efficacy <--- Safety1 .004 .965
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Table	11.	Main	characteristics	of	medicines	whose	ATC	Code	has	a	percentage	distribution	up	to	6
ATC Code
Generic 
vs non 
Generic
Approval 
time
Measure 
of 
Efficacy
Efficiency/ 
Safety
Low 
Efficiency/ 
Safety
Further 
Indication 
vs No 
Further 
Indication
Further 
indication / 
Efficiency
1. Alimentary 
tract 
and metabolism
3.54 
vs 11
third 
semester
disease 
reduction 
progress 
rate
2nd class- 
medium 
efficiency/ 
safety with high- 
medium safety 
related
the highest 
among 
percentges in 
class 
3rd -low 
efficiency
4.5 vs 9.5
1st and 2nd 
class 
high and 
medium 
efficiency
3. Cardiovascular 
system
1.57 
vs 6.27
fifth 
semester 
and beyond
care rate, 
disease 
reduction 
progress 
rate, 
reduction 
of 
symptoms
2nd class- 
medium 
efficiency/ 
safety with high- 
medium safety 
related
low percentage 
in class 3rd- 
low efficiency
1.5 vs 6.5
2nd class 
medium 
efficiency
7. Anti-infectives 
for 
systemic use
1.18 vs 
11.37
first and 
second 
semester
care rate
1st class -high 
efficiency with 
high- medium 
safety related
no data in class 
3rd- 
low efficiency
6.0 vs 8.5
1st and 2nd 
class 
high and 
medium 
efficiency
8. Antineoplastic
3.15 vs 
20.08
first and 
second 
semester
overall 
survival
1st -high 
efficiency with 
low safety 
related
low percentage 
in class 
3rd- low 
efficiency 
with related 
safety 
omogeneously 
distributed in 
high-mediun-low
10.0 vs 15.5
1st and 2nd 
class 
high and 
medium 
efficiency
10. Nervous 
system
6.69 vs 
7.87
first 
semester
reduction 
of 
symptoms
2st -medium 
efficiency with 
medium -low 
safety related
low percentage 
in 3rd class- low 
efficiency 
with related high 
and low safety.
2.0 vs 8.0
1st and 2nd 
class 
high and 
medium 
efficiency
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ENDNOTES
1  Authors thank one referee for having stressed this aspect.
2  The Anatomical Therapeutic Chemical (ATC) Classification System is used for the classification 
of active ingredients of drugs according to the organ or system on which they act and their thera-
peutic, pharmacological and chemical properties. It is controlled by the World Health Organization 
Collaborating Centre for Drug Statistics Methodology (WHOCC)
3  We just reported EMA term of classification (side effect), without further investigating the nature 
of adverse reactions. This was deemed sufficient at this stage of analysis.
